Intra-arterial infusion chemotherapy for invasive bladder cancer

Tomoyasu Tsushima, Masatake Takamatsu, Shin Ebara, Shunko Kaku, Takanori Murakami, Yoshiyuki Miyaji, Yasuo Yamamoto, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Ohmori, Satoshi Uno, Ryouji Arata, Kenji Aramaki, Taiichiro Johsen, Michinao Saegusa, Takafumi Akagi, Yujiro Ozaki, Kohji Shidahara, Yasuki Nakayama, Teruaki Akaeda

Research output: Contribution to journalArticle

Abstract

A total of 57 patients with invasive bladder cancer (T2 4, N0, M0) was treated with arterial infusion chemotherapy and their treatment outcome was evaluated. Each patient was given 70 mg/m2 of CDDP and 40 mg/m2 of ADM. During the treatment, 2 μg/min of angiotensin II were also administrated. Of 56 evaluable patients, CR was obtained in 9 patients, PR in 32, NC in 14 and PD in 1, providing an overall response rate of 73%. Following arterial infusion chemotherapy, total cystectomy was performed in 24 patients while bladder sparing therapy was performed in 32 patients. The follow up duration ranged from 3 to 128 months (median 34 months, average 41 months). The cause specific 5 year survival rate was 54% and the median survival duration was 61 months. Among patients treated with the bladder sparing approach, the cause specific 5 year survival rate was 65% and the event free 5 year survival rate was 26%, with the median event free duration being 29 months. The pathological T stage was lower than the clinical T stage in 12 out of 24 patients treated with total cystectomy, while the cause specific 5 year survival rate was 43%. Although the clinical response to this arterial infusion chemotherapy was encouraging, a bladder sparing approach based on this therapy was of only limited success. It remains unclear whether or not arterial infusion chemotherapy can improve prognosis for total cystectomy patients.

Original languageEnglish
Pages (from-to)263-267
Number of pages5
JournalNishinihon Journal of Urology
Volume59
Issue number4
Publication statusPublished - Apr 1997

Fingerprint

Intra Arterial Infusions
Urinary Bladder Neoplasms
Drug Therapy
Cystectomy
Survival Rate
Urinary Bladder
Angiotensin II
Therapeutics
Survival

Keywords

  • ADM
  • angiotensin II
  • CDDP
  • intra arterial infusion chemotherapy
  • invasive bladder cancer

ASJC Scopus subject areas

  • Urology

Cite this

Tsushima, T., Takamatsu, M., Ebara, S., Kaku, S., Murakami, T., Miyaji, Y., ... Akaeda, T. (1997). Intra-arterial infusion chemotherapy for invasive bladder cancer. Nishinihon Journal of Urology, 59(4), 263-267.

Intra-arterial infusion chemotherapy for invasive bladder cancer. / Tsushima, Tomoyasu; Takamatsu, Masatake; Ebara, Shin; Kaku, Shunko; Murakami, Takanori; Miyaji, Yoshiyuki; Yamamoto, Yasuo; Nasu, Yasutomo; Kumon, Hiromi; Ohmori, Hiroyuki; Uno, Satoshi; Arata, Ryouji; Aramaki, Kenji; Johsen, Taiichiro; Saegusa, Michinao; Akagi, Takafumi; Ozaki, Yujiro; Shidahara, Kohji; Nakayama, Yasuki; Akaeda, Teruaki.

In: Nishinihon Journal of Urology, Vol. 59, No. 4, 04.1997, p. 263-267.

Research output: Contribution to journalArticle

Tsushima, T, Takamatsu, M, Ebara, S, Kaku, S, Murakami, T, Miyaji, Y, Yamamoto, Y, Nasu, Y, Kumon, H, Ohmori, H, Uno, S, Arata, R, Aramaki, K, Johsen, T, Saegusa, M, Akagi, T, Ozaki, Y, Shidahara, K, Nakayama, Y & Akaeda, T 1997, 'Intra-arterial infusion chemotherapy for invasive bladder cancer', Nishinihon Journal of Urology, vol. 59, no. 4, pp. 263-267.
Tsushima T, Takamatsu M, Ebara S, Kaku S, Murakami T, Miyaji Y et al. Intra-arterial infusion chemotherapy for invasive bladder cancer. Nishinihon Journal of Urology. 1997 Apr;59(4):263-267.
Tsushima, Tomoyasu ; Takamatsu, Masatake ; Ebara, Shin ; Kaku, Shunko ; Murakami, Takanori ; Miyaji, Yoshiyuki ; Yamamoto, Yasuo ; Nasu, Yasutomo ; Kumon, Hiromi ; Ohmori, Hiroyuki ; Uno, Satoshi ; Arata, Ryouji ; Aramaki, Kenji ; Johsen, Taiichiro ; Saegusa, Michinao ; Akagi, Takafumi ; Ozaki, Yujiro ; Shidahara, Kohji ; Nakayama, Yasuki ; Akaeda, Teruaki. / Intra-arterial infusion chemotherapy for invasive bladder cancer. In: Nishinihon Journal of Urology. 1997 ; Vol. 59, No. 4. pp. 263-267.
@article{f9bfbec6ab7746e984c735fd889a9af0,
title = "Intra-arterial infusion chemotherapy for invasive bladder cancer",
abstract = "A total of 57 patients with invasive bladder cancer (T2 4, N0, M0) was treated with arterial infusion chemotherapy and their treatment outcome was evaluated. Each patient was given 70 mg/m2 of CDDP and 40 mg/m2 of ADM. During the treatment, 2 μg/min of angiotensin II were also administrated. Of 56 evaluable patients, CR was obtained in 9 patients, PR in 32, NC in 14 and PD in 1, providing an overall response rate of 73{\%}. Following arterial infusion chemotherapy, total cystectomy was performed in 24 patients while bladder sparing therapy was performed in 32 patients. The follow up duration ranged from 3 to 128 months (median 34 months, average 41 months). The cause specific 5 year survival rate was 54{\%} and the median survival duration was 61 months. Among patients treated with the bladder sparing approach, the cause specific 5 year survival rate was 65{\%} and the event free 5 year survival rate was 26{\%}, with the median event free duration being 29 months. The pathological T stage was lower than the clinical T stage in 12 out of 24 patients treated with total cystectomy, while the cause specific 5 year survival rate was 43{\%}. Although the clinical response to this arterial infusion chemotherapy was encouraging, a bladder sparing approach based on this therapy was of only limited success. It remains unclear whether or not arterial infusion chemotherapy can improve prognosis for total cystectomy patients.",
keywords = "ADM, angiotensin II, CDDP, intra arterial infusion chemotherapy, invasive bladder cancer",
author = "Tomoyasu Tsushima and Masatake Takamatsu and Shin Ebara and Shunko Kaku and Takanori Murakami and Yoshiyuki Miyaji and Yasuo Yamamoto and Yasutomo Nasu and Hiromi Kumon and Hiroyuki Ohmori and Satoshi Uno and Ryouji Arata and Kenji Aramaki and Taiichiro Johsen and Michinao Saegusa and Takafumi Akagi and Yujiro Ozaki and Kohji Shidahara and Yasuki Nakayama and Teruaki Akaeda",
year = "1997",
month = "4",
language = "English",
volume = "59",
pages = "263--267",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "4",

}

TY - JOUR

T1 - Intra-arterial infusion chemotherapy for invasive bladder cancer

AU - Tsushima, Tomoyasu

AU - Takamatsu, Masatake

AU - Ebara, Shin

AU - Kaku, Shunko

AU - Murakami, Takanori

AU - Miyaji, Yoshiyuki

AU - Yamamoto, Yasuo

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Uno, Satoshi

AU - Arata, Ryouji

AU - Aramaki, Kenji

AU - Johsen, Taiichiro

AU - Saegusa, Michinao

AU - Akagi, Takafumi

AU - Ozaki, Yujiro

AU - Shidahara, Kohji

AU - Nakayama, Yasuki

AU - Akaeda, Teruaki

PY - 1997/4

Y1 - 1997/4

N2 - A total of 57 patients with invasive bladder cancer (T2 4, N0, M0) was treated with arterial infusion chemotherapy and their treatment outcome was evaluated. Each patient was given 70 mg/m2 of CDDP and 40 mg/m2 of ADM. During the treatment, 2 μg/min of angiotensin II were also administrated. Of 56 evaluable patients, CR was obtained in 9 patients, PR in 32, NC in 14 and PD in 1, providing an overall response rate of 73%. Following arterial infusion chemotherapy, total cystectomy was performed in 24 patients while bladder sparing therapy was performed in 32 patients. The follow up duration ranged from 3 to 128 months (median 34 months, average 41 months). The cause specific 5 year survival rate was 54% and the median survival duration was 61 months. Among patients treated with the bladder sparing approach, the cause specific 5 year survival rate was 65% and the event free 5 year survival rate was 26%, with the median event free duration being 29 months. The pathological T stage was lower than the clinical T stage in 12 out of 24 patients treated with total cystectomy, while the cause specific 5 year survival rate was 43%. Although the clinical response to this arterial infusion chemotherapy was encouraging, a bladder sparing approach based on this therapy was of only limited success. It remains unclear whether or not arterial infusion chemotherapy can improve prognosis for total cystectomy patients.

AB - A total of 57 patients with invasive bladder cancer (T2 4, N0, M0) was treated with arterial infusion chemotherapy and their treatment outcome was evaluated. Each patient was given 70 mg/m2 of CDDP and 40 mg/m2 of ADM. During the treatment, 2 μg/min of angiotensin II were also administrated. Of 56 evaluable patients, CR was obtained in 9 patients, PR in 32, NC in 14 and PD in 1, providing an overall response rate of 73%. Following arterial infusion chemotherapy, total cystectomy was performed in 24 patients while bladder sparing therapy was performed in 32 patients. The follow up duration ranged from 3 to 128 months (median 34 months, average 41 months). The cause specific 5 year survival rate was 54% and the median survival duration was 61 months. Among patients treated with the bladder sparing approach, the cause specific 5 year survival rate was 65% and the event free 5 year survival rate was 26%, with the median event free duration being 29 months. The pathological T stage was lower than the clinical T stage in 12 out of 24 patients treated with total cystectomy, while the cause specific 5 year survival rate was 43%. Although the clinical response to this arterial infusion chemotherapy was encouraging, a bladder sparing approach based on this therapy was of only limited success. It remains unclear whether or not arterial infusion chemotherapy can improve prognosis for total cystectomy patients.

KW - ADM

KW - angiotensin II

KW - CDDP

KW - intra arterial infusion chemotherapy

KW - invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=8244239017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244239017&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:8244239017

VL - 59

SP - 263

EP - 267

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 4

ER -